ArticleArchives of microbiology2026
Antimicrobial and antibiofilm effects of Lactobacillus cell-free supernatants against standard and antibiotic-resistant Pseudomonas aeruginosa and Staphylococcus aureus.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm-producing pathogens, including multidrug-resistant Pseudomonas aeruginosa and Staphylococcus aureus, pose significant clinical challenges within medical settings. Eradication of the biofilm remains a challenging mission, prompting ongoing scientific research for effective solutions. This research investigated the high antimicrobial and antibiofilm capacity of cell-free supernatants (CFS) from Lacticaseibacillus casei PTCC 1608 and Lactobacillus acidophilus PTCC 1643 against these challenging-to-treat pathogens. We tested these Lactobacilli's CFS antibacterial potential against P. aeruginosa ATCC 27,853, S. aureus ATCC 25,923, P. aeruginosa PAO1, and methicillin-resistant Staphylococcus aureus (MRSA; UTMC 1442) by the microdilution technique to find out the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. Subsequently, the inhibitory and disruptive capacity of the CFS for established biofilms was tested at concentrations corresponding to their respective MIC and MBC values. Ultimately, the chemical characterization of Lactobacillus supernatant compositions by the gas chromatography-mass spectrometry (GC-MS) technique helped reveal the antibacterial and antibiofilm-active organic compounds. Notably, the P. aeruginosa ATCC 27,853 biofilm was significantly eliminated by L. casei and L. acidophilus supernatants at 3×MBC by 88.39 ± 3.6% and 80.47 ± 6.3%, respectively. Furthermore, at ¼ MIC, L. casei inhibited MRSA biofilm by 80.17 ± 6.2%. Acetic acid derivatives, lactic acid, and phthalic acid were identified by GC-MS analysis as important constituents of the Lactobacillus supernatants. Further confirmed by electron microscopy, our findings highlight strong in vitro antibiofilm and antibacterial activities of indigenous Iranian Lacticaseibacillus casei PTCC 1608 and Lactobacillus acidophilus PTCC 1643 supernatants. These results suggest their potential as natural sources of bioactive compounds that could be further explored for developing biotherapeutic strategies against biofilm-associated infections and antibiotic resistance.
Indexed as
Identifiers
42250125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.